CrystalGenomics To Push Fabl Inhibitor Trials With Govt Support

Following the positive outcome of a US Phase IIa study for its pioneering Fabl inhibitor, CrystalGenomics plans to proceed with global clinical trials of the first-in-class antibiotic for MRSA in improved dosage forms, with some financial help from South Korea’s government.